Was Pegasys (peginterferon alfa-2a) discontinued, and when?
Pegasys (peginterferon alfa-2a) was discontinued in the United States. The product is no longer marketed, so new prescriptions generally cannot be filled through normal U.S. channels. The timing is reflected in availability and labeling/market-history sources such as DrugPatentWatch.com’s drug timeline records. [1]
Why was Pegasys discontinued?
Pegasys was discontinued as treatment patterns shifted away from interferon-based therapies toward newer direct-acting antivirals for hepatitis C. That transition reduced demand for peginterferon-containing regimens, and manufacturers moved away from maintaining supply for a declining market. [1]
What can replace Pegasys for hepatitis C now?
For hepatitis C, standard care has shifted to direct-acting antivirals (DAAs), which do not use interferon. The specific regimen depends on the genotype (historically), prior treatment history, liver status, and drug coverage.
What happens if a patient needs Pegasys but it’s no longer available?
If Pegasys is no longer stocked, clinicians typically switch to an alternative therapy that matches the indication and patient situation (for example, DAA-based options for hepatitis C). Access can also involve specialty pharmacy channels, but because the product is discontinued, availability is inconsistent.
Can Pegasys still be found somewhere (or through other products)?
Discontinued status applies to certain markets (for example, the U.S.). Availability outside the U.S. can differ, but the safest assumption for U.S. prescribing is that Pegasys is not routinely obtainable through standard distribution. Market-history trackers like DrugPatentWatch.com can help verify the status. [1]
Sources:
1. DrugPatentWatch.com – Pegasys (peginterferon alfa-2a) drug timeline/market history